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Distal hereditary motor neuropathies are a rare subgroup of inherited peripheral neuropathies hallmarked by a length-dependent
axonal degeneration of lower motor neurons without signiﬁcant involvement of sensory neurons. We identiﬁed patients with
heterozygous nonsense mutations in the aII-spectrin gene, SPTAN1, in three separate dominant hereditary motor neuropathy
families via next-generation sequencing. Variable penetrance was noted for these mutations in two of three families, and phenotype
severity differs greatly between patients. The mutant mRNA containing nonsense mutations is broken down by nonsense-mediated
decay and leads to reduced protein levels in patient cells. Previously, dominant-negative aII-spectrin gene mutations were described
as causal in a spectrum of epilepsy phenotypes.
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Introduction
Inherited peripheral neuropathies, the most common type
of inherited neuromuscular disease, are a group of dis-
orders with marked clinical and genetic heterogeneity.
Hereditary motor neuropathies (HMN) are a rarer sub-
group among inherited peripheral neuropathies, causing a
length-dependent axonal degeneration of lower motor neu-
rons typically without obvious involvement of sensory neu-
rons. Depending on the subtype, patients may present with
distal atrophy and muscle weakness, whereas proximal in-
volvement only develops later in the disease progression.
Foot malformations as well as other additional clinical
characteristics including pyramidal signs, vocal fold and
diaphragm paralysis can be present (Rossor et al., 2012).
The widespread introduction of next-generation sequen-
cing (NGS) techniques over the past decade has allowed
for rapid disease gene identiﬁcation, with currently over 90
inherited peripheral neuropathy-associated genes, as well as
detailed investigation of genotype-phenotype correlations. As
such it has become clear that the idea of one gene, one
phenotype is oversimpliﬁed and does not capture the true
complexity of most Mendelian diseases. There are numerous
examples of distinct phenotypes caused by mutations in dif-
ferent genes, as well as mutations in one gene causing diver-
gent clinical entities sometimes even impacting different
organ systems (Boerkoel et al., 2002; Montenegro et al.,
2018). One of the more extreme genes is LMNA, in which
mutations have been described causing Emery-Dreifuss mus-
cular dystrophy, several types of dilated cardiomyopathy,
atrial ﬁbrillation, Charcot-Marie-Tooth disease (CMT) and
Hutchinson-Gilford progeria (Tazir et al., 2013;
Montenegro et al., 2018). HMN has been shown to display
similar genetic pleiotropy, by genetic overlap with other
neuromuscular disorders such as amyotrophic lateral sclerosis
(ALS) and congenital myasthenic syndrome, shown by mu-
tations in SETX, SIGMAR1 and SLC5A7 (Chen et al., 2004;
Munch et al., 2004; Al-Saif et al., 2011; Salter et al., 2018).
Similarly, overlap with CNS diseases was shown for AARS
mutations, which are also known to cause early-onset epilep-
tic encephalopathy (Simons et al., 2015).
SPTAN1 is a gene initially associated with a spectrum of
epilepsy phenotypes (Syrbe et al., 2017). Currently, 36 in-
dividuals with 24 different dominant SPTAN1 variants
have been reported, of which 11 are missense variants,
10 are in-frame deletions/duplications, two are truncating
mutation and one is a splice variant (Syrbe et al., 2017;
Gartner et al., 2018). More recently, mutations in SPTAN1
have been described in patients with complex neurodeve-
lopmental phenotypes (Gartner et al., 2018). Furthermore,
microdeletions encompassing one or more genes including
SPTAN1 and STXBP1, another causal epilepsy gene, have
been reported to be responsible for complex phenotypes
with combinations of early-onset primary dystonia, epi-
lepsy, and intellectual disability (Stamberger et al., 2016;
Syrbe et al., 2017).
Here, we describe three families with dominantly in-
herited HMN carrying different heterozygous SPTAN1
nonsense variants identiﬁed by NGS. These families show
great variability in clinical severity and these mutations are
incompletely penetrant in at least two individuals. Because
of the nature of the mutations and the loss of protein ex-
pression in mutation carriers, we suspect a mechanism of
haploinsufﬁciency of aII-spectrin could be causative for the
HMN phenotype.
Materials and methods
Genetic studies
DNA and lymphoblast extraction was performed on peripheral
blood samples obtained from patients and family members
after informed consent. All experiments described were
approved by the ethical committee of the University of
Antwerp. DNA for next generation sequencing was enriched
for target regions using the Nextera Rapid Capture Expanded
Exome kit (62Mb) with the prepared library sequenced on an
Illumina HiSeq 2500. Data annotation and variant ﬁltering
were performed using the Clinical Sequence Analyzer and
Miner (Wuxi NextCODE). Either whole-genome (Families A
and C) or whole-exome (Family B) sequencing was performed
on Individuals A:I:1, A:II:2, A:III:1, B:II:2, B:III:2, B:IV:1,
C:III:2 and C:III:3 (Fig. 1A–C).
Variants in known genes for inherited peripheral neur-
opathy, ALS, myopathy, ataxia and hereditary spastic paraple-
gia were investigated ﬁrst. Non-synonymous, in-frame
deletions/insertions and predicted loss-of-function variants
with a population frequency of 50.5% and CADD 420
were withheld for follow-up by dideoxy sequence analysis
(Rentzsch et al., 2019). As no segregating variants in known
genes were present, the same ﬁltering was used on all protein-
coding genes. Upon identiﬁcation of the SPTAN1 variants,
co-segregation with the phenotype within each family was con-
ﬁrmed using dideoxy sequence analysis. Primer sequences are
available upon request.
We performed subsequent targeted panel sequencing of
SPTAN1 on an additional 95 HMN patients, which revealed
no additional causal variants in SPTAN1, indicating that
SPTAN1 loss-of-function mutations are rare.
Genome-wide significance testing
We calculated the signiﬁcance of ﬁnding three inherited loss-
of-function mutations in our HMN NGS cohort consisting of
73 families, by using a python-based version of SORVA soft-
ware (Rao and Nelson, 2018).
Heterozygous loss-of-function variants in SPTAN1 in the
general population with a minor-allele frequency 50.05 as
queried by SORVA results in a frequency of 0.0. Further cal-
culations were not possible using this frequency. Therefore, we
used a frequency of 3.13  104 as determined by all pre-
dicted loss-of-function mutations present in gnomAD, includ-
ing variants with loss-of-function ﬂags (Lek et al., 2016).
Subsequently, we subdivided our cohort into groups with
different coefﬁcients of relationships: 1 for index pairs, 0.5
for index/parent pairs and 0.25 for sibling pairs and tri-
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generational families. The calculated P-value was adjusted by
Bonferroni correction and multiplied by the number of genes
sequenced, which for NGS is 24 000.
Preparation of patient lymphoblasts
Patient lymphoblast cell lines were cultured in RPMI 1640
medium with 10% foetal bovine serum (FBS), 1% L-glutamine,
1% penicillin/streptomycin and 1% sodium pyruvate and
maintained at 37C with 6% CO2. To assess nonsense-
mediated decay (NMD) parallel split cells from the same pa-
tient were exposed to cycloheximide (100 ng/ml in dimethyl
sulphoxide (DMSO)] or DMSO incubated for 4 h at 37C.
Another, parallel split of cells was kept untreated.
Cycloheximide experiments were performed three consecutive
times.
Dideoxy sequencing for assessment of
nonsense-mediated decay of mutated
allele
Primers for cDNA ampliﬁcation of the three mutations were
designed, sequences are available upon request. Messenger
RNA extraction from lymphoblast cell pellets treated with
cycloheximide, DMSO or non-treated was performed by
RNeasy mini kit (Qiagen). Subsequently, DNase treatment
(Ambion) and cDNA synthesis was performed by
SuperScriptTM III (Thermo Fisher Scientiﬁc) according to
manufacturer’s protocol. PCR ampliﬁcation of cDNA was per-
formed using Titanium Taq DNA polymerase (Takarabio)
according to manufacturer’s protocol.
Western blotting
For western blot, untreated lymphoblast cell pellets were trea-
ted with RIPA lysate buffer, containing protease and phosphat-
ase inhibitors. Protein concentration was measured by BCA
assay kit (Invitrogen) according to the manufacturer’s proto-
col. Ten micrograms per sample were loaded onto a
NuPAGE 4–12% gradient Bis-Tris SDS-PAGE gel (Thermo
Fisher Scientiﬁc), SeeBlue Plus2 prestained ladder (Thermo
Fisher Scientiﬁc) was used as a size reference. Wet transfer
was performed onto nitrocellulose blotting paper. Subsequent
blocking was performed using 5% skimmed milk powder in
phosphate-buffered saline with Tween (PBST). A primary
mouse anti-SPTAN1 antibody (1:1000) was used (Abcam
ab11755). A rabbit-anti-mouse IgG2b HRP-conjugated sec-
ondary antibody was used. Stripping and reprobing for
GAPDH (Genetex GTX100118 1:10 000) was performed to
Figure 1 Pedigrees of families with SPTAN1 mutations. (A–C) Pedigrees of Families A–C with their respective mutation segregation of
variants (NM_003127: c.415C4T), (NM_003127: c.4615C4T) and (NM_003127: c.6385C4T) showing affected (black), and unaffected (white)
individuals. Those clinically and genetically investigated are indicated by a hash symbol and a mutation result, carrier ( + /) and non-carrier (/),
respectively.
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assess equal loading across all samples. For each blot a new
lysate was used.
Quantiﬁcation using ImageJ over six different western blots,
was performed measuring the band density. All quantiﬁcations
were performed on 16-bit images with signals in the linear
range and did not contain saturated bands. SPTAN1 expres-
sion was normalized by GAPDH expression per sample per
blot. GAPDH-normalized SPTAN1 expression levels are
plotted per individual.
TritonTM X-100 solubility assay
Primary lymphoblasts of three affected (Individuals A:III:1,
B:IV:I, C:III:2) and three control (Individuals A:III3, B:III:3,
C:IV:1) individuals were cultured as described previously.
Cells (10  106) were pelleted and lysed with the following
lysis buffer [50 mM Tris-HCL (pH 7.5), 150mM NaCl,
5mM EDTA and 1% TritonTM X-100 (v/v) with protease in-
hibitors (Life Technologies)] on ice for 20min. Subsequent
centrifugation at 14 000 rpm for 10min at 4C resulted in a
soluble and insoluble fraction. The insoluble fraction was re-
suspended and sonicated with 10  1-s bursts at 50% ampli-
tude and 0.6 pulse rate. Twenty micrograms of protein were
loaded NuPAGE 4–12% gradient Bis-Tris SDS-PAGE gel
(Thermo Fisher Scientiﬁc), SeeBlue Plus2 prestained ladder
(Thermo Fisher Scientiﬁc) was used as a size reference.
Western blotting proceeded as described previously. a-
Tubulin (ab7291 1:5000) staining was performed as a loading
control.
Preparation of patient fibroblasts
Fibroblasts were obtained from skin biopsies from the pro-
bands of Families A–C (Individuals A:III:1, B:IV:1 and
C:III:2). For all ﬁbroblast experiments an unrelated control
ﬁbroblast cell line was used. Fibroblast cultures were main-
tained in Dulbecco’s modiﬁed Eagle medium high glucose
(Thermoﬁsher) with 10% FBS, 1% penicillin/streptomycin
and 1% L-Glutamine and kept at 37C and 5% CO2.
Immunocytochemistry
Fibroblasts were seeded onto a SensoplateTM 96-well plate
with lid (Greiner) at 5  103 cells per well. Cells were incu-
bated over night at 37C and 5% CO2. Cells were then ﬁxed
in 4% paraformaldehyde and blocked at room temperature
with normal goat serum (1:500) in PBT (sterile PBS with
0.5% v/v TritonTM X-100 and 0.5% w/v BSA). Overnight
incubation at 4C with a primary mouse anti-SPTAN1
(1:200) (ab11755) and room temperature incubation with a
goat-anti-mouse 488 Alexa Fluor secondary antibody were
performed. Subsequently, F-actin staining was performed
with Alexa Fluor 594-conjugated phalloidin (1.5 units/ml,
30min, Life Technologies) and Hoechst 33342 nuclear stain-
ing was applied (1 mg/ml, 20min Life Technologies). Image
stacks (1024  1024 pixels; pixel size 130 nm  130 nm) com-
prising the entire cell depth were taken with a Zeiss LSM700
confocal microscope using a 40 /1.30 Plan Neoﬂuar object-
ive. Possible cross-talk of the ﬂuorescence channels was
excluded by using frame-by-frame scanning. Maximum inten-
sity projections and image crops were made with ImageJ2
(Rueden et al., 2017).
Data availability
The raw NGS data supporting the ﬁndings in patients cannot
be made publicly available for conﬁdentiality reasons. All
other data generated or analysed during this study are included
herein and in the Supplementary material.
Results
Genetic findings
We performed whole-exome or whole-genome sequencing
in a cohort of 73 families with HMN. Initial analysis of
variants in genes with known associations with neuropathy
or related neuromuscular disorders identiﬁed no segregat-
ing variants in NGS performed on three individuals in
Family A (Individuals A:I:1; A:II:2 and A:III:1), three af-
fected individuals in Family B (Individuals B:II:2, B:III:2
and B:IV:1) and two affected siblings in Family C
(Individuals C:III:1 and C:III:2). Subsequent analysis of
all segregating variants in protein coding genes yielded
nonsense mutations in SPTAN1 in all three families:
Family A (NM_003127: c.415C4T p.R139*), Family B
(NM_003127: c.4615C4T p.Q1539*) and Family C
(NM_003127: c.6385C4T p.Q2149*). Based on predic-
tion scores, the absence of the variant in population data-
bases gnomAD and ExAC, the predicted high intolerance
for loss-of-function mutation, and the segregation of the
variant within the NGS data, these SPTAN1 variants are
the most likely cause for the HMN phenotype in these
families (Supplementary Table 2) (Lek et al., 2016).
Subsequently, all variants were conﬁrmed by dideoxy se-
quence analysis and found to co-segregate within each
family consistent with autosomal dominant transmission
(Fig. 1A–C). Identiﬁcation of three loss-of-function variants
in our HMN cohort consisting of 73 families reaches
genome-wide signiﬁcance as calculated using SORVA
(P = 6.2  105) (Rao and Nelson, 2018).
Clinical findings
The patients carrying heterozygous SPTAN1 nonsense mu-
tations presented here, show lower limb weakness as result
of a length-dependent motor neuropathy. In general, the
phenotype is a juvenile onset slowly progressive axonal
motor neuropathy (Table 1). However, the clinical pheno-
type is highly variable both inter- and intrafamilially,
mainly in terms of severity (Table 1). As such, there are
two possibly asymptomatic carriers, Individuals B:II:3 and
C:II:2. Individual B:II:3 was clinically examined, but
showed no indications for an axonal motor neuropathy
phenotype, no EMG or nerve conduction studies (NCS)
were performed. Individual C:II:2 was not clinically evalu-
ated, based on hearsay she does not suffer from a motor
neuropathy. It could be that Individual C:II:2 is mosaic for
the mutation and does not carry the mutation in the tissues
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affected in a neuropathy phenotype. DNA was extracted
from hair and buccal swap from Individual C:II:2.
Dideoxy sequencing showed the presence of the mutation
in both hair, blood and buccal sample, thus we could not
conﬁrm Individual C:II:2 as a mosaic carrier.
As there was an existing association between SPTAN1
mutations and epilepsy, we considered the possibility of
our patients showing a similar phenotype in addition to
the HMN phenotype. However, unlike patients previously
described with heterozygous SPTAN1 mutations, none of
the individuals in this study showed symptoms or signs of
epilepsy, intellectual disability and hearing or visual loss, as
such no formal investigations were performed. All individ-
uals examined had normal school and professional careers
and were capable to start families, none of the patients
were care-dependent or living in residential facilities.
Since no brain MRIs were performed, structural (asymp-
tomatic) brain abnormalities cannot be excluded. With ex-
ception of Individual B:III:2, who takes levothyroxine to
treat a postpartum subclinical hypothyroidism, there were
no indications for a thyroid abnormality as previously iden-
tiﬁed in two patients (Table 1) (Gartner et al., 2018).
Family A
The ﬁrst family’s proband (Individual A:III:1; Fig. 1A) pre-
sented with early-onset gait difﬁculties from the age of
6 years, resulting in easily sprained ankles and frequent
falls. She has a bilateral toe drop and is unable to walk
on the heels. The overall progression is slow as the patient
is able to walk unaided at the age of 30 years. She has
atrophy of the intrinsic foot muscles and slight atrophy
of the lower legs. Reﬂexes in both lower and upper limbs
are normal. NCS showed normal motor and sensory con-
duction velocities and slightly decreased compound muscle
action potentials, ﬁtting with a distal length-dependent
axonal neuropathy (Supplementary Table 1).
The mother of the proband (Individual A:II:2) is less af-
fected, although she mentions similarly frequent sprained
ankles and frequent falls. She has a limited ability to
walk on the heels and a slight bilateral toe drop but re-
mains ambulatory at age 59 years. The grandfather of the
proband (Individual A:I:1) was previously diagnosed with
axonal neuropathy. While the grandfather is now wheel-
chair-bound due to a hip fracture after a fall, he previously
struggled with gait difﬁculties but had been ambulatory
until age 62. The proband’s aunt (Individual A:II:4),
uncle (Individual A:II:5) and cousin (Individual A:III:2) all
reported no symptoms before clinical investigation, but
upon inspection show slightly decreased strength of the
foot dorsiﬂexors and a toe drop.
Family B
The second family’s proband (Individual B:IV:1; Fig. 1B)
presented with early-onset gait difﬁculties from the age of
3 years, with weakness in the lower limbs, and a mildly
shortened Achilles tendons. He reported no sensory in-
volvement. The deep tendon reﬂexes were reduced in the
lower limbs and normal in the upper limbs. The NCS indi-
cated a neurogenic rather than myogenic disorder and
showed ﬁndings ﬁtting with an axonal motor predominant
neuropathy. The proband was initially diagnosed as a pa-
tient with distal SMA. Both the proband’s mother
(Individual B:III:2) and grandmother (Individual B:II:2)
were mildly affected and showed weakness of dorsal exten-
sion with preserved reﬂexes, pes planus and calf hypotro-
phy. Both underwent NCS, which showed results
compatible with neuronal degradation indicative of pure
motor axonal neuropathy mainly affecting the lower
limbs (Supplementary Table 1). Most recently, Individual
B:IV:2, the younger brother of the proband (Individual
B:IV:1) showed weakness in the lower limbs, presenting
as an inability to walk on heels starting at the age of 3
years. He shows no weakness in the upper limbs. An NCS
performed at age 5, showed ﬁndings compatible with a
motor predominant axonal neuropathy. None of the mem-
bers of the family showed pyramidal symptoms
(Supplementary Table 1).
Family C
The third proband (Individual C:III:2; Fig. 1C) presented
with walking difﬁculties from the age of 9 years, with in-
ability to run and frequent falls. Shortly after, she under-
went orthopaedic surgery to correct a bilateral Achilles
tendon shortening. The motor difﬁculties progressed very
slowly and the patient is able to walk at age 59 with a
cane, but with a marked steppage gait. Deep tendon
reﬂexes are absent in the lower limbs and reduced in the
upper limbs. Distal leg hypotrophy is evident. In the past 2
years, mild weakness and atrophy of the hands and distal
arm muscles was observed. She reports mild touch
hypoesthesia and reduced dexterity. NCS in this patient
support a distal axonal motor predominant neuropathy
(Supplementary Table 1).
The proband’s younger brother (Individual C:III:3)
showed similar walking difﬁculties from the age of 12
years, but is able to walk unaided at the age of 52. The
non-consanguineous parents reported no motor disabilities
at age 93 and 87 years old. The proband has two children
(Individuals C:IV:1 and C:IV:2) of 38 and 34 years, re-
spectively, who both have a normal phenotype.
SPTAN1 nonsense mutations cause
loss-of-expression
SPTAN1 (NM_003127) comprises 56 exons encoding the
2472 amino acid long wild-type aII-spectrin protein. The
aII-spectrin protein (SPTAN1) is a major component of the
spectrin skeleton where it forms antiparallel tetramers made
of heterodimers of two aII and two b-spectrin units. A
single aII-spectrin protein consists of 20 spectrin repeats,
a SH3 domain and two EF hand domains. The C-terminal
spectrin repeats are coiled coils involved in dimerization
with b-spectrin, whereas the two EF-hand domains are
thought to be able to interact and modulate the actin-
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binding domains of the b-spectrin (Broderick and Winder,
2005; Machnicka et al., 2014). Mutations causing epilepsy
and HMN do not seem to be linked to speciﬁc regions or
domains of the protein, although the C-terminus seems en-
riched for in-frame deletions and insertions (Fig. 2). A
recent study by Gartner et al. (2018) identiﬁed a nonsense
mutation in a patient without epilepsy and hypothesized a
haploinsufﬁciency mechanism. To investigate whether the
nature of these nonsense mutations indeed results in a hap-
loinsufﬁciency of aII-spectrin, we performed expression stu-
dies on mRNA and protein level by PCR and Sanger
sequencing and western blot respectively.
We assessed whether the mutant mRNA is broken down
by the NMD pathway by exposing patient lymphoblast to
cycloheximide inhibiting the NMD pathway (Durand et al.,
2007). DMSO was used as a vehicle control. In the non-
treated samples, the mutant allele is only slightly present,
indicating an almost complete breakdown of the allele
(Fig. 3). Inhibition of the NMD pathway by cycloheximide
shows an increased presence of the mutant allele, conﬁrm-
ing that the breakdown of the mutant allele under basal
conditions is due to the NMD pathway activity (Fig. 3).
These results are similar for all three mutations, conﬁrming
a similar mechanism despite different mutational locations.
In addition, we assessed expression on protein level by
means of western blot of patient and control lymphoblast
whole-cell lysates. Comparing protein expression between
patient and controls of the same family we observed a clear
decrease of wild-type aII-spectrin expression in patients
lymphoblasts, but again not in their unaffected family
members (Fig. 4A and B). No additional bands of other
sizes, besides the expected aII-spectrin cleavage product at
150 kDa were observed.
aII-Spectrin nonsense mutations do
not impact protein solubility or
localization
To assess the differences between the previously reported
mutations and our nonsense mutations, we investigated the
soluble and insoluble fractions aII-spectrin by western blot
as well as the presence and localization of aggregate for-
mation of aII-spectrin in patients carrying SPTAN1 non-
sense mutations.
Both for the patient (Individuals A:III:1, B:IV:1, C:III:2)
and control (Individuals A:III:3, B:III:3, C:IV:1) lympho-
blast cell lines aII-spectrin was mainly present in the soluble
fractions, although there was a clear insoluble aII-spectrin
fraction present in all cell lines. We observed no enrichment
of aII-spectrin in the insoluble fraction for any of the cell
lines (Fig. 4C).
Next, we assessed the localization of aII-spectrin in pa-
tient (Individuals A:III:1, B:IV:1 and C:III:2) and unrelated
control ﬁbroblasts by immunocytochemistry. No differ-
ences were detected between patients and the control
cells (Fig. 4D). Most aII-spectrin was present in small
puncta spread over the cytoplasm. In addition, plasma
membrane zones with increased aII-spectrin intensity
could be observed in all samples. No aII-spectrin aggre-
gates could be detected.
Figure 2 Graphical representation of SPTAN1 with mutations identified in epilepsy and HMN patients. Graphical representation of
SPTAN1 protein wherein all previously reported SPTAN1 mutations have been indicated with their reference between brackets as well as the
hereditary motor neuropathy-associated mutations discussed in this study indicated in red and by (x). Previously reported mutation as identified
by: 1, Gilissen et al. (2014); 2, Syrbe et al. (2017); 3, Hamdan et al. (2012); 4, Yavarna et al. (2015); 5, Retterer et al. (2016); 6, Saitsu et al. (2010); 7,
Writzl et al. (2012); 8, Nonoda et al. (2013); 9, Tohyama et al. (2015); 10, Ream and Mikati (2014); 11, Rapaccini et al. (2018); 12, Stavropoulos et al.
(2016); and 13, Gartner et al. (2018).
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Discussion
In this study we identiﬁed three nonsense mutation in
SPTAN1 by means of NGS in three unrelated families
with an inherited peripheral motor neuropathy phenotype.
The ﬁrst family (Family A) consists of a proband, her af-
fected mother, grandfather, aunt, uncle and cousin all car-
rying the p.(R139*) mutation. In this family, all affected
individuals share symptoms of frequent falls and sprained
ankles, as well as bilateral toe-drop and atrophy of intrinsic
foot muscles to varying degrees. These symptoms and the
NCS in the proband and cousin, support a mild length-
dependent axonal motor neuropathy or HMN.
The second family (Family B) consists of a proband, and
his affected bother, mother and grandmother with an
HMN phenotype, who carry a p.(Q1539) mutation. In
this family the phenotype consists of lower limb weakness,
in some individuals combined with reduced reﬂexes, and
electrophysiological ﬁndings supporting a length-dependent
axonal motor predominant neuropathy in different degrees
of severity.
The third family (Family C) consists of a proband and
her affected brother. They both carry the p.(Q2129*) mu-
tation. For this family the phenotype is characterized by
(early) childhood onset gait difﬁculties with inability to
walk on the heels. Mild distal weakness of the upper
limbs was noted in the eldest patient. Clinical ﬁndings in
this family are consistent with a length-dependent axonal
motor neuropathy. Interestingly, none of the described pa-
tients show any clinical signs of epilepsy, intellectual dis-
ability or ataxia, symptoms previously associated with
other heterozygous SPTAN1 mutations (Syrbe et al.,
2017; Gartner et al., 2018).
Although the mutations segregate appropriately for an
autosomal dominant disorder within each family, there
are several individuals with mild phenotypes and possibly
two asymptomatic carriers, which suggests variable pene-
trance of these mutations. In similar fashion, the gnomAD
database contains a number of predicted loss-of-function
variants, but still predicts very high loss-of-function intoler-
ance for SPTAN1 indicated by a pLi score of 1.0 and an
oe-score of 0.06 (observed versus expected variants ratio)
(Lek et al., 2016). It is conceivable that the individuals in
gnomAD are only mildly affected or asymptomatic as
reduced penetrance is not novel in patients with heterozy-
gous loss-of-function mutations (Cooper et al., 2013). This
also applies to SPAST, in which loss-of-function mutations
are known to cause familial spastic paraplegia, with prom-
inent variation in severity as well as reduced penetrance
(Shoukier et al., 2009). Even for SCN1A in which loss-
of-function mutation are a well-known cause linked to
the severe early-onset phenotype Dravet syndrome, several
predicted loss-of-function mutations are present in
gnomAD (Claes et al., 2001). Therefore, some degree of
caution is warranted when querying such databases.
Previously, SPTAN1 mutations have been associated with
a spectrum of epilepsy phenotypes (Syrbe et al., 2017).
Several SPTAN1 missense and in-frame deletions/insertions
are disease causing in a putative dominant-negative fashion
indicated by SPTAN1 aggregates (Syrbe et al., 2017). The
presence of aggregates in some epilepsy patients with in-
frame deletion or insertions seems to be an effect limited to
speciﬁc mutations in the C-terminal region and not a uni-
versal characteristic for all SPTAN1 mutations as indicated
by our results and a recent report (Syrbe et al., 2017;
Gartner et al., 2018). This would ﬁt with the current under-
standing that especially C-terminal spectrin repeats are im-
portant for b-spectrin heterodimerization (Broderick and
Winder, 2005). However, as these aggregates are only
prominent in C-terminal mutations (and absent in one
Figure 3 SPTAN1 assessment of nonsense-mediated decay and mRNA. Mutation carrier ( + /) and non-carrier (/) sanger
sequencing traces per mutation (NM_003127: c.415C4T), (NM_003127: c.4615C4T) and (NM_003127: c.6385C4T) showing effect of
cycloheximide (CHX) and DMSO (vehicle control) treatment on mRNA breakdown of mutant allele in comparison to basal conditions depicted
by the non-treated (NT) samples. Representative images of three independent experiments are shown.
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Figure 4 Comparison of SPTAN1 protein expression, solubility and staining pattern in patients versus controls. (A) Protein
expression on western blot probing for SPTAN1 and GAPDH (loading control) (cropped images) of mutation carriers ( + /) and non-carriers
(/), respectively. (B) Box-and-whisker plot representation of GAPDH normalized SPTAN1 expression levels per individual. x-axis represents
SPTAN1 expression values normalized for GAPDH per individual. Error bars represent the minimal and maximal observed values and median and
lower and upper quartile shown. (C) Soluble (sol) and insoluble (in) protein fractions per individual with western blot probing for SPTAN1 and
actin (loading control) (cropped images), for mutation carriers ( + /) and non-carriers (/), respectively (D) Immunocytochemical staining of
aII-spectrin in cultured skin fibroblasts of a healthy non-related control and of three patients, each carrying a different HMN causing mutation
(Individuals A:III:1, B:IV:1 and C:III:2). Hoechst 33342 staining for the nucleus (cyan) and fluorophore-conjugated phalloidin staining for F-actin
(magenta) was performed to counterstain aII-spectrin (yellow). Stars indicate clear stretches of aII-spectrin accumulations at the plasma mem-
brane. Scale bar = 20 mm.
Alpha-II-spectrin in motor neuropathies BRAIN 2019: 142; 2605–2616 | 2613
D
ow
nloaded from
 https://academ
ic.oup.com
/brain/article-abstract/142/9/2605/5536902 by G
hent U
niversity user on 10 January 2020
tested missense variant and nonsense variants), further in-
vestigation is needed to know if these aggregates are asso-
ciated with all types of mutations in the C-terminal region
and whether this correlates with the phenotypes identiﬁed
in patients. It would be of special interest to see if b-spec-
trin function would be impaired due to the formation of
these aggregates and the putative loss of stability (Saitsu
et al., 2010), as b-spectrin loss in Drosophila melanogaster
results in a more severe phenotype than loss of a-spectrin.
This may in turn translate to the more severe developmen-
tal phenotype observed in patients with C-terminal muta-
tions in SPTAN1 (Pielage et al., 2005).
Recently, mutations in SPTAN1 have been associated
with a complex phenotype including intellectual disability,
hypoplastic brain structures and ﬁne and gross motor im-
pairments without epilepsy (Gartner et al., 2018). Gartner
et al. suggest a loss of wild-type mRNA and haploinsufﬁ-
ciency mechanism for their nonsense mutant and demon-
strate that ﬁbroblasts in this patient have reduced wild-type
levels of SPTAN1 protein. In our three families, we were
able to show that these nonsense variants result in a mutant
allele with premature stop codon, which is mostly degraded
on mRNA level by means of NMD. In addition, we observe
60–80% aII-spectrin protein expression in patients when
compared with controls, higher than the expected 50%,
possibly indicating some degree of expression compensation
by increased wild-type translation. Interestingly, expression
levels of SPTAN1 protein do not seem to correlate with the
intrafamilial or interfamilial differences in disease severity
in the limited number of families investigated in this study.
In the past, multiple neurodevelopmental patients with
microdeletions in the 9q34.11 region have been reported
and these deletions often span multiple dosage-sensitive
genes resulting in a contiguous gene deletion syndrome
(Saitsu et al., 2010; Campbell et al., 2012). However,
microdeletions encompassing the region with SPTAN1, do
not necessarily give rise to an epilepsy phenotype, as indi-
cated by several patients with a deletion that does not in-
clude STXBP1, and who do not have an epilepsy
phenotype (Campbell et al., 2012). This supports the
belief that speciﬁc loss of SPTAN1, as seen in these
HMN patients and the patients described by Gartner
et al., can be causal for a phenotype without epilepsy
(Gartner et al., 2018). Currently, no whole gene deletions
of SPTAN1 only have been described.
SPTAN1 plays an important role in stabilizing the spec-
trin-dependent cytoskeleton and the deﬁnition of nodal,
paranodal and juxtaparanodal membrane domains in neu-
rons (Pielage et al., 2005; Huang et al., 2017a). While the
spectrin skeleton is abundantly present in both the periph-
eral and central nervous system (Goodman et al., 1995;
Bennett and Baines, 2001), its role in the postembryonic
nervous system is elusive. The role of the cytoskeleton in
peripheral neuropathies is well known as mutations in mul-
tiple cytoskeletal associated proteins have been associated
with inherited peripheral neuropathy, including DST (cyto-
skeleton linker protein), NEFL (intermediate ﬁlament for
maintenance of cytoskeleton) and GAN (binds to microtu-
bule-associated protein 1B) (Bomont et al., 2000;
Jordanova et al., 2003; Edvardson et al., 2012).
Deletion of orthologues to the aII-spectrin gene from
Drosophila, Caenorhabditis elegans and Mus musculus
lead to embryonic lethality, showing aII-spectrin is essential
for cellular development and function (Lee et al., 1993;
Featherstone et al., 2001; Norman and Moerman, 2002).
Speciﬁc loss of presynaptic a-spectrin was shown to lead to
increased synapse retractions in Drosophila neuromuscular
junction including a larger number of boutons as well as
disruption of retrograde transport (Pielage et al., 2005).
Both synapse retractions and disrupted retrograde transport
have been reported for a number of genes causative for
motor neuron disorders including; DCNT1 and SOD1
(ALS), and DYNC1H1 (CMT) (Murakami et al., 2001;
Hafezparast et al., 2003; Zhou et al., 2016), supporting
the conclusion that reduced aII-spectrin levels could be cap-
able of inducing a degenerative synapse retraction, leading
to the axonal degeneration causal in HMN (Massaro et al.,
2009).
Previously, speciﬁc loss of aII-spectrin in peripheral sen-
sory neurons in mice was shown to have a length-depend-
ent degenerative effect (Huang et al., 2017b). The authors
showed that the aII-spectrin-dependent cytoskeleton is dis-
pensable for maintenance of small diameter axons but is
essential for axon integrity in large diameter myelinated
axons. Upon increased aII-spectrin levels, larger diameter
axons could be protected from degeneration (Huang et al.,
2017b). Compared to the much shorter and thinner CNS
axons, lower motor neurons might be more susceptible to
damage, as the extraordinary length and larger diameter of
their axons requires highly efﬁcient processes of cellular
signaling (Huang et al., 2017b). It is therefore conceivable
that large calibre lower motor neuron axons are sensitive to
moderate reductions in overall aII-spectrin levels which
could provide a potential explanation for the manifestation
of an HMN phenotype upon nonsense mutations in
SPTAN1. Also, the phenotype severity could be dependent
upon the degree of reduction in protein expression levels.
However, this requires further detailed investigation of
more patients with various causal SPTAN1 mutations,
since it might be that they all have some degree of lower
motor neuron degeneration. Especially in the severe syn-
dromic phenotypes it might be that mild peripheral nervous
system involvement is lost in the global severity of the clin-
ical presentation.
A point of interest is that heterozygous Spna2/SPTAN1
knockout mice do not seem to show a phenotype, therefore
indicating that SPTAN1 haploinsufﬁciency is tolerated in
these animals (Stankewich et al., 2011). While heterozy-
gous (Spna2+ /) mice were morphologically indistinguish-
able from wild-type animals, they also showed similar
protein expression levels, which is unlike what we observe
in heterozygous patients and this might inﬂuence the
phenotypic outcome (Stankewich et al., 2011; Gartner
et al., 2018). It is possible that there is a feedback loop
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in mice, leading to increased Spna2 protein expression from
the one wild-type allele. However, it is also known that not
all genes that are intolerant to haploinsufﬁciency in humans
prove to be so in mice, and ﬁnally the effect of the genetic
background of the mice can also have a signiﬁcant effect on
the penetrance of many phenotypes. It is worth further
investigating mice of different strains starting from the as-
sumption that a pathological phenotype might only be pre-
sent upon clear loss of Spna2 protein expression, since this
would better model the situation in patients with SPTAN1
nonsense mutations.
With the increased number of SPTAN1 mutations iden-
tiﬁed and the ever-increasing phenotypic variability, it is
clear that further systematic assessment of the mutational
differences in aII-spectrin protein and mRNA levels as well
as the possible underlying mechanisms (dominant-negative,
gain-of-function and haploinsufﬁciency) is necessary. Such
systematic studies should aim to look at the different mu-
tations associated with the epilepsy spectrum, including the
C-terminal in-frame deletions and insertions as well as mis-
sense mutations. Non-epilepsy mutations should include the
milder HMN phenotype described here as well as the more
complex developmental phenotype (Gartner et al., 2018).
In conclusion, we present three families with dominantly
inherited SPTAN1 nonsense mutations and a hereditary
motor neuropathy phenotype, expanding the SPTAN1-
associated phenotype spectrum. This study corroborates
nonsense mutations and partial loss of aII-spectrin as a
mechanism causal for peripheral nervous system motor
axon degeneration. In addition, we show that SPTAN1
mutations do not always lead to phenotypes that include
epilepsy and that disease severity can be highly variable.
The exact pathomechanisms underlying the differences
and similarities exhibited by SPTAN1 mutations and
phenotypes require further investigation.
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